MedTrace Logo

Characterization of the Metabolic Fate of an Oral Arginine Form

NCT02352740 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2015-02-02

No results posted yet for this study

Summary

The purpose of this study is to compare the metabolic fate of two oral forms of L-Arginine in healthy subjects featuring metabolic syndrome related risk factors

Conditions

Interventions

DIETARY_SUPPLEMENT

A form Arginine

3 capsules containing 0.5g of A form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week

DIETARY_SUPPLEMENT

B form Arginine

3 capsules containing 0.5g of B form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week

Sponsors & Collaborators

  • Institut de Recherche Pierre Fabre

    collaborator OTHER

  • Hospital Avicenne

    collaborator OTHER

  • Adeprina

    collaborator OTHER

  • Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement

    lead OTHER

Principal Investigators

  • Robert Benamouzig · Hospital Avicenne

  • François Mariotti, PhD · AgroParisTech

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2013-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02352740 on ClinicalTrials.gov